858 Therapeutics

About:

858 Therapeutics develops small molecule drugs targeting oncology and immunology.

Top Investors: Insight Partners, New Enterprise Associates, Cormorant Asset Management, Alexandria Venture Investments, Avidity Partners

Description:

858 Therapeutics is a biotechnology company focused on discovering small molecule therapeutics for novel targets in oncology and immunology. The company emphasizes innovative approaches in synthetic lethality, innate immunity, and RNA modulation. Its lead program is a PARG inhibitor currently in early clinical development.

Total Funding Amount:

$130M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2019-01-01

Contact Email:

info(AT)8five8tx.com

Founders:

Gretchen Bain, Jeffrey Stafford, Jim Veal

Number of Employees:

11-50

Last Funding Date:

2024-09-26

IPO Status:

Private

Industries: